Gilead's Hep C Med the Most Costly for Medicare, Medicaid in 2015

Published: Nov 15, 2016

The latest dive into Medicaid and Medicare prescription drug data shows that the federal health care programs spent more on the Harvoni hepatitis C treatment last year than any other medicine.

Medicare Part D spent slightly more than $7 billion on the Gilead Sciences product, while Medicaid coughed up nearly $2.2 billion for the drug, according to data released today by the Centers for Medicare and Medicaid Services.

The agency released its latest dashboard, an interactive tool that chose a few dozen drugs for which spending or unit costs rose by notable amounts, as well as those brand and generic medicines that contributed to large program spending overall.

Back to news